Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;91(11):1132-1136.
doi: 10.1136/jnnp-2020-323016. Epub 2020 Aug 7.

Humans: the ultimate animal models

Mary M Reilly  1 , Alexander M Rossor  2
Affiliations
Review

Humans: the ultimate animal models

Mary M Reilly et al. J Neurol Neurosurg Psychiatry. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Phenotypes associated with inherited peripheral neuropathies. Charcot-Marie-Tooth (CMT) disease types 1 and 2 are defined by a predominant demyelinating or axonal peripheral neuropathy, respectively. Hereditary motor neuropathy (HMN) and hereditary sensory neuropathy (HSN) represent phenotypic extremes and show significant overlap with CMT2. Many other more complex neurological diseases such as hereditary spastic paraplegia, ataxia and optic atrophy may also develop a peripheral neuropathy and in a minority this may be the presenting feature. RP, retinitis pigmentosa.
Figure 2
Figure 2
A disease model must mirror the changes that occur in the human body during normal ageing.
See this image and copyright information in PMC

References

    1. Petrov D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci 2017;9:68. 10.3389/fnagi.2017.00068 - DOI - PMC - PubMed
    1. Pipis M, Rossor AM, Laura M, et al. Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges. Nat Rev Neurol 2019;15:644–56. 10.1038/s41582-019-0254-5 - DOI - PubMed
    1. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22–31. 10.1056/NEJMoa1716793 - DOI - PMC - PubMed
    1. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11–21. 10.1056/NEJMoa1716153 - DOI - PubMed
    1. Barreto LCLS, Oliveira FS, Nunes PS, et al. Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review. Neuroepidemiology 2016;46:157–65. 10.1159/000443706 - DOI - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts